Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (LGVN) director Arjun JJ Desai reported an acquisition of 36,000 shares of Class A common stock on August 19, 2026. The transaction was a grant of time-based vesting Restricted Stock Units (RSUs) at a stated price of $0.00 per share, bringing Desai’s directly held position to 36,000 shares, which includes RSUs subject to future vesting.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (LGVN) reported that Chief Medical Officer Nataliya Agafonova received an equity compensation award. She was granted 286,000 shares of Class A Common Stock in the form of time-based vesting Restricted Stock Units (RSUs), acquired at a stated price of $0.00 per share as an award. After this grant, her directly held position is 716,914 shares of Class A Common Stock, which includes RSUs subject to future vesting.
Longeveron Inc. (LGVN) director Deborah Ascheim reported an acquisition of 36,000 shares of Class A Common Stock on 2026-08-19 through a grant/award, reflected at a price of $0.00 per share. The award represents time-based vesting Restricted Stock Units (RSUs) and includes RSUs subject to future vesting, bringing her reported direct holdings to 36,000 shares.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (LGVN) appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 17, 2026. He brings over 25 years of biopharma and biotech leadership experience, including prior CFO roles at Opus Genetics, Insilico Medicine and Journey Medical Corporation. Former CFO Marie Washburn will remain with Longeveron, returning to her prior position as Vice President and Corporate Controller.
Under a Letter Agreement, Jhaveri will receive an initial base salary of $400,000 per year, a performance-based annual cash incentive target of 45% of base salary, and eligibility for short- and long-term equity incentives under the company’s 2021 Incentive Award Plan. As of the effective date, he will receive an equity grant of 300,000 Restricted Stock Units, vesting quarterly over three years. A press release also highlights Longeveron’s lead stem cell therapy, laromestrocel (Lomecel-B), and notes that top-line results from the Phase 2b HLHS trial are anticipated in September of this year.
Longeveron Inc. received an amended Schedule 13G from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership position in the company’s Class A common stock.
As of the close of business on June 30, 2026, the reporting group may be deemed to beneficially own 2,941,180 shares of Class A common stock, all issuable upon exercise of a warrant held by Intracoastal. These shares represent approximately 9.0% of the Class A common stock, based on 29,697,332 shares outstanding as of May 5, 2026 plus the warrant shares. Additional warrants held by Intracoastal for 162,766 and 745,342 shares are excluded from this calculation due to 4.99% beneficial ownership blocker provisions. Without these blocker provisions, the reporting persons may have been deemed to beneficially own 3,849,288 shares of Class A common stock. Voting and dispositive power over the 2,941,180 warrant shares is reported on a shared basis.
Longeveron Inc., a clinical-stage biotech developing the allogeneic cell therapy laromestrocel (Lomecel-B) for four indications including HLHS, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy and Aging-related Frailty, reported financial results for the quarter and six months ended June 30, 2026 and highlighted upcoming clinical milestones, including a planned September top-line data readout from the ELPIS II Phase 2b HLHS trial.
For the quarter, clinical trial revenue was $0.287 million, with no contract manufacturing revenue, producing gross profit of $0.182 million. Operating expenses were $6.353 million, leading to a net loss of $6.073 million and a six-month net loss of $10.809 million. As of June 30, 2026, the company reported cash and cash equivalents of approximately $10.1 million, total assets of $15.487 million, stockholders’ equity of $10.402 million, and an accumulated deficit of $143.120 million. The company also notes multiple FDA regulatory designations for laromestrocel, including Orphan Drug, Fast Track, Rare Pediatric Disease and RMAT designations across its HLHS and Alzheimer’s programs.
Longeveron Inc., a clinical-stage biotech focused on regenerative cell therapies, reported a net loss of $10.8 million for the six months ended June 30, 2026, on revenue of $0.7 million, primarily from clinical trial activity. Operating expenses remained high at $11.4 million, reflecting research and development and general and administrative spending.
Cash and cash equivalents increased to $10.1 million from $4.7 million at year-end 2025, driven mainly by $13.5 million of net equity proceeds from a March 2026 private placement, $1.4 million from warrant exercises, and $0.9 million from the sale of an interest in 50% of potential PRV proceeds. Stockholders’ equity rose to $10.4 million.
The company states that existing cash is expected to fund operations only into the fourth quarter of 2026 and that additional financing will be required. Management’s cash flow forecast indicates insufficient resources to meet minimum commitments over 12 months, leading to disclosed substantial doubt about the ability to continue as a going concern. Subsequent to quarter-end, Longeveron was named a finalist in the XPRIZE Healthspan competition, entitling it to a $1.0 million milestone award earmarked for a future clinical trial.